A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (NCT06925737)
A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)
🩺 Plain-English Summary (8th-Grade Level)
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic in Arizona - Phoenix ( Site 0044) — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (295 Sites)
Showing the first 25 of 295 sites.
- Mayo Clinic in Arizona - Phoenix ( Site 0044) — Phoenix, Arizona
- City of Hope Comprehensive Cancer Center ( Site 0049) — Duarte, California
- City of Hope Lennar Foundation Cancer Center ( Site 0059) — Irvine, California
- Moores Cancer Center ( Site 0010) — La Jolla, California
- Veterans Affairs Long Beach Healthcare System ( Site 0058) — Long Beach, California
- Cedars-Sinai Medical Center ( Site 0068) — Los Angeles, California
- UCLA Hematology/Oncology - Santa Monica ( Site 0002) — Los Angeles, California
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0006) — Orange, California
- Stanford Cancer Center ( Site 0046) — Palo Alto, California
- Rocky Mountain Regional Veterans Affairs Medical Center ( Site 0053) — Aurora, Colorado
- Yale-New Haven Hospital-Yale Cancer Center ( Site 0050) — New Haven, Connecticut
- Veterans Affairs Connecticut Healthcare System ( Site 0062) — West Haven, Connecticut
- The GW Medical Faculty Associates ( Site 0057) — Washington D.C., District of Columbia
- Washington DC Veterans Affairs Medical Center ( Site 0056) — Washington D.C., District of Columbia
- Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0077) — Jacksonville, Florida
- Emory University School of Medicine- Grady Campus ( Site 0103) — Atlanta, Georgia
- Winship Cancer Institute, Emory University ( Site 0003) — Atlanta, Georgia
- Rush University Medical Center-Hematology and Oncology ( Site 0028) — Chicago, Illinois
- University of Illinois at Chicago-University of Illinois Cancer Center ( Site 0063) — Chicago, Illinois
- University of Kentucky Chandler Medical Center ( Site 0048) — Lexington, Kentucky
- Greenebaum Comprehensive Cancer Center ( Site 0021) — Baltimore, Maryland
- Beth Israel Deaconess Medical Center ( Site 0043) — Boston, Massachusetts
- Dana Farber Cancer Institute ( Site 0012) — Boston, Massachusetts
- University of Michigan ( Site 0005) — Ann Arbor, Michigan
- Henry Ford Hospital ( Site 0035) — Detroit, Michigan
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostate Cancer
- A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC — Homewood, Alabama
- A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described — Homewood, Alabama
- Stereotactic Ablative Radiation Therapy for Prostate Cancer — Charleston, South Carolina
- A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer — Basking Ridge, New Jersey
- A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer — Phoenix, Arizona
- Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer — Baltimore, Maryland
Explore by condition: All Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.